UTERINE FIBROIDS IN EARLY REPRODUCTIVE AGE WOMEN: FEATURES OF MORPHOLOGY, HORMONAL STATUS AND REHABILITATION

Abstract

The object of the study: Uterine fibroids (UF) in women of early reproductive age. The problem to be solved: Improving the effectiveness of postoperative rehabilitation in women of early reproductive age with uterine fibroids based on the study of its morphological features and improvement of rehabilitation measures. The main scientific results: It was found that in women of early reproductive age with UF the most common complaints are posthemorrhagic anemia (61.0 %, or 61 women). Regarding the menstrual cycle, the most common dysmenorrhea – 26.0 % (in 26 women). The importance of heredity in the development of such pathology in young women (32.0 %, or 32 women) was confirmed. The most common localization of fibroids is interstitial – 79.0 % (in 79 women). Morphological study found that women of early reproductive age most often have a simple UF, namely 96 % (96 women). Uterine leiomyoma was present in 56 % (56 women). A study of the hormonal status of women of early reproductive age found that the mean values ​​of hormones such as follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, progesterone, prolactin and testosterone were higher before surgery than after. When comparing rehabilitation methods (combined oral contraceptives (COCs) or gonadotropin-releasing hormone agonists (GnRH agonists), it was found that postoperative rehabilitation by using COCs for 6-12 months provides significantly better indicators of recovery of hormonal status, indicating the effectiveness of rehabilitation method. Scope of practical application of research results: Practical medicine specializing in the diagnosis, treatment and prevention of recurrence of uterine fibroids. Innovative technological product: Improved algorithm of postoperative rehabilitation measures by applying COC for 6-12 months after myomectomy, which provides significantly better results in restoring hormonal status during rehabilitation. Scope of application of innovative technological product: clinical medical practice related to the diagnosis, treatment and prevention of recurrence of uterine fibroids.